E
Erik De Clercq
Researcher at Rega Institute for Medical Research
Publications - 1499
Citations - 63353
Erik De Clercq is an academic researcher from Rega Institute for Medical Research. The author has contributed to research in topics: Virus & Reverse transcriptase. The author has an hindex of 106, co-authored 1447 publications receiving 59200 citations. Previous affiliations of Erik De Clercq include Auburn University & University of Warsaw.
Papers
More filters
Journal ArticleDOI
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
Rudi Pauwels,Jan Balzarini,Masanori Baba,Robert Snoeck,Dominique Schols,Piet Herdewijn,Jan Desmyter,Erik De Clercq +7 more
TL;DR: A rapid, sensitive and automated assay procedure was developed for the in vitro evaluation of anti-HIV agents, which significantly reduced labor time as compared to the trypan blue exclusion method, and permits the evaluation of large numbers of compounds for their anti-hIV activity.
Journal ArticleDOI
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Guangdi Li,Erik De Clercq +1 more
TL;DR: The potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19) is discussed, some of which are already moving into clinical trials.
Journal ArticleDOI
Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives
Rudi Pauwels,Koen Andries,Jan Desmyter,Dominique Schols,Michael J. Kukla,Henry J. Breslin,Alfons Raeymaeckers,Jozef H L Van Gelder,Robert Woestenborghs,J. Heykants,K. H. L. Schellekens,Marcel August Constant Janssen,Erik De Clercq,Paul A. J. Janssen +13 more
TL;DR: In this article, a series of tetrahydro-imidazone derivatives of Benzodiazepin-2(1H)-one and -thione (TIBO) derivatives were found to inhibit the replication of HIV-1 and HIV-2.
Journal ArticleDOI
Angiogenesis : regulators and clinical applications
TL;DR: As basic knowledge about the control of angiogenesis and its role in tumor growth and metastasis increases, it may be possible in the future to develop specific anti-angiogenic agents that offer a potential therapy for cancer and angiogenic diseases.
Journal ArticleDOI
A novel selective broad-spectrum anti-DNA virus agent.
TL;DR: It is reported that, in mice and rabbits in vivo, the compound is effective against both local and systemic infections with herpes simplex virus type 1, including herpetic keratitis caused by a TK− mutant which is resistant to the classical anti-herpes drugs.